|
Hamster Response
- Immune Response: A viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. (Tran et. al 2021)
- Side Effects: Nanocovax did not induce any adverse effects in mice (Mus musculus var. albino) and rats (Rattus norvegicus). (Tran et. al 2021)
|
Hamster Response
- Immune Response: Hamsters administered 2 doses of VXA-CoV2-1 showed a reduction in weight loss and lung pathology and had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G, and neutralizing antibodies were induced upon oral immunization with the sera, demonstrating neutralizing activity. (Johnson et al., 2022)
- Efficacy: Overall, these data demonstrate the ability of oral vaccine candidate VXA-CoV2-1 to provide protection against SARS-CoV-2 disease. (Johnson et al., 2022)
|
Tran et. al 2021: Thi Nhu Mai Tran, Bruce Pearson May, Trong Thuan Ung, Mai Khoi Nguyen, Thi Thuy Trang Nguyen, Van Long Dinh, Chinh Chung Doan 1, The Vinh Tran 1, Hiep Khong 1, Thi Thanh Truc Nguyen 1, Hoang Quoc Huy Hua 1, Viet Anh Nguyen 1, Tan Phat Ha 1, Dang Luu Phan 1, Truong An Nguyen 1, Thi Ngoc Bui 1, Tieu My Tu 1, Thi Theo Nguyen 1, Thi Thuy Hang Le 1, Thi Lan Dong 1, Trong Hieu Huynh 1, Phien Huong Ho 1, Nguyen Thanh Thao Le 1, Cong Thao Truong 1, Hoang Phi Pham 1, Cong Y Luong 1, Nie Lim Y 1, Minh Ngoc Cao 1, Duy Khanh Nguyen 1, Thi Thanh Le 2, Duc Cuong Vuong 2, Le Khanh Hang Nguyen 2, Minh Si Do 1. Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19. . 2021; ; . [PubMed: 34938290].
|
Johnson et al., 2022: Susan Johnson 1, Clarissa I Martinez 1, Sarah N Tedjakusuma 1, Nadine Peinovich 1, Emery G Dora 1, Sharla M Birch 2, Adriana E Kajon 2, Adam D Werts 2, Sean N Tucker 1. Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model. . 2022; ; . [PubMed: 34758086].
|
